GlassScriptPhysician profile
Jeffrey P Levine
NPI 1841379377
$195,134.81
in general payments reported to CMS, 2019-2025
17 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $16K · 2021: $35K · 2022: $30K · 2023: $20K · 2024: $39K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $51K · Consulting Fee: $16K · Travel and Lodging: $6,105 · Food and Beverage: $1,354 · Honoraria: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $51,005.69 |
| Consulting Fee | $16,018.00 |
| Travel and Lodging | $6,104.59 |
| Food and Beverage | $1,353.90 |
| Honoraria | $972.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $102,656.35 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $41,298.92 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40,436.99 | 2019-2025 | |
| Coopersurgical, INC. | $8,705.75 | 2019-2024 | Paragard T 380a |
| Medicines360 | $1,359.35 | 2019-2021 | |
| Roche Molecular Systems, INC. | $200.00 | 2022 | |
| Exact Sciences Corporation | $113.96 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $77.15 | 2019-2025 | Evenity, Prolia, Prolia |
| Amag Pharmaceuticals, INC. | $74.99 | 2019 | |
| Myovant Sciences INC. | $44.42 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.70 | 2020-2021 | |
| Boston Scientific Corporation | $34.02 | 2019 | |
| Smith+Nephew, INC. | $22.11 | 2024 | Pico 7 |
| Radius Health, INC. | $21.09 | 2024 | Tymlos |
| Therapeuticsmd, INC. | $20.80 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $18.99 | 2025 | Gemtesa |
| Abbvie INC. | $15.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.